KINETICfinder: A disruptive method to determine kinetic profiles in drug discoveries

Project Information

KINETICfinder

Grant agreement ID: 867659

DOI

10.3030/867659

Project closed

EC signature date 24 May 2019

Start date 1 June 2019

End date 30 November 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

ENZYMLOGIC SL
Spain

Periodic Reporting for period 1 - KINETICfinder (KINETICfinder: A disruptive method to determine kinetic profiles in drug discoveries)

Reporting period: 2019-06-01 to 2019-11-30

Summary of the context and overall objectives of the project

Bringing a new drug to the market costs €2,600M and takes 12 years. Around 80% of drugs under research do not reach clinical trials. Pharma industry has selected only those potential drugs that have high financial return. There are 26 million people suffering from Alzheimer's, which leads to $600M in expenses per year. Diabetes killed 1.6 million people in 2016. Deaths due to dementias doubled from 2000, making it the 5th leading cause of global deaths in 2016. These trends show the need for a game changing solution that will improve patients’ life expectancy and contribute to a more sustainable healthcare system. ENZYMLOGIC aims to become a leading company in the niche of kinetic drug analysis. It has validated a reduction of time and cost by 50% in the pathway of a new drug from research to market.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Enzymlogic has validated the technical feasibility of KINETICfinder where GPCR was implemented. The robustness and sensitivity achieved are above the standard criteria in the pharma industry. The accuracy and reproducibility of data has been demonstrated and it is an environmentally friendly platform, reducing significantly the number of animals used in preclinical trials and avoiding the use of contaminating radioactive residues. In the business viability, Enzymlogic has validated the market niche of drug development analysis from an early stage worldwide, already having 3 customer of the top-10 global market. The area of biotechnological drugs also has a significant growth of 14.1%. Drugs are regarding cancer-targeted therapies and Alzheimer's disease as the most researched. The scalability analysis shows that due to the highly processability of the process. The revenue model based on a “Pay per Service” procedure has been validated, but some other revenues approaches will not be developed. A high-skilled commercial team will be required to keep the relationships with worldwide top-twenty Enzymlogic’s customers. In addition, the IPR strategy has been developed to protect further stages and once the technical, economic and commercial viability has been proven, Enzymlogic has already a complete business plan.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Actions are expected to demonstrate clear exploitation potential and socioeconomic benefits for patients and sustainable health systems. KINETICfinder will contribute to solve the following socio-economic challenges, facilitating new fast routes to develop drugs for complex diseases and overcome resistances. Aditionally, KINETICfinder is environmentally-friendly.

ipr-strategy.jpg